AGC Acquires Biomeva
News Sep 06, 2016
AGC Asahi Glass announces that it has acquired all of the shares of Biomeva GmbH from Biomeva Holding GmbH. Biomeva is one of the leading biopharmaceutical contract manufacturing organizations (CMO) in Europe. With Biomeva now a part of the AGC Group, AGC’s Life Science Business will be offering wider geographic coverage and a wider range of capacities.
Based in the Bio Cluster City of Heidelberg, Germany, Biomeva has almost 25 years of experience in providing contract development and manufacturing services using microbial expression technology to European and other International customers. Biomeva’s services include process development for highly efficient therapeutic protein expression, cGMP compliant fermentation, purification and bulk filling, as well as analytical testing and cell banking.
Dr. Thomas Pultar, CEO of Biomeva says “By combining Biomeva’s capabilities and AGC’s large scale manufacturing capacities we will generate a new and strong international microbial CMO, offering the complete services from process development to large scale market supply. To me, this is a perfect synergy between Biomeva’s strength in clinical manufacturing and AGC’s expertise and capacity for commercial production. I look forward to continuing my role as CEO of Biomeva under this new ownership.”
In a new study in cells, University of Illinois researchers have adapted CRISPR gene-editing technology to cause the cell’s internal machinery to skip over a small portion of a gene when transcribing it into a template for protein building. This gives researchers a way not only to eliminate a mutated gene sequence, but to influence how the gene is expressed and regulated.